Stats

A diagnostic test was run on the MIRM stock using the CLI momentum strategy with the following parameters: momentum20, stop5%, target10%, and days730 on the IEX exchange. The test was then repeated with the same engine and strategy, but this time with a holdout period from 2026 to September 8, using the previous 20 bars for warmup and flat warmup trading. The results of the holdout period were: fund catalyst, symbol MIRM, 191 bars, return percentage 22.16509767375947, buy and hold percentage 40.20284547119313, maximum drawdown percentage 15.199708089039069, win rate 50, average trade percentage 1.5664072813636993, and the total number of trades was 16. However, an inspection of the engine code revealed that it does not account for fees or slippage, and it uses a same-close signal entry and stop fills at the exact stop price, even if the price gaps below it. This is contradicted by the actual ledger and a 15-minute gap audit. As a result, the positive gross results cannot be trusted, and no parameters were selected for live use. The buy-and-hold percentage includes the warmup period and should not be used to calculate the excess return. The data was sourced from https://runway.adityaperswal.workers.dev/data/stock-bars, and additional tests were run using the vectorbt calendar with exposure audit to answer questions about the strategy.

A diagnostic test was run on the IONS stock using a momentum strategy with specific parameters: momentum20, stop5%, target10%, and days730. The test was done on a dataset from IEX and then the same strategy was applied to a different dataset for training until 2025 and for testing from 2026 until September 8. The test results showed a return of -14.070477285394468% for the strategy, compared to -30.70625610948192% for a buy-and-hold approach. The strategy had a maximum drawdown of 18.321309831926% and a win rate of 31.25%. The average trade return was -0.8359489928864545%. The test was done with 20 prior bars for warmup and flat warmup trading, and a total of 191 bars were used for the holdout test. The results also showed that the strategy had 16 trades. An inspection of the code showed that it did not account for fees or slippage, and that stop losses were filled at the exact stop price even if the price gapped below it. However, this is not consistent with actual trading data, which showed gaps in prices. Therefore, the positive results of the test cannot be trusted, and no parameters were selected for live use. The buy-and-hold return includes the warmup period and should not be used to calculate the excess return of the strategy. The data used for the test came from https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all. Additional tests were done using a costed vectorbt calendar, but this diagnostic test did not provide information on position size.

A diagnostic test was run on the CLI momentum strategy with the following parameters: momentum20, stop5%, target10%, and days730 on the IEX exchange. The test was then imported and run on a different dataset, with a holdout period from 2026 to September 8, and 20 prior bars for warmup. The results of the holdout period for the symbol RARE were as follows: 191 bars, return percentage of 1.8975920520518441%, buy and hold return percentage of -59.17695473251029%, maximum drawdown percentage of 22.621906250000023%, win rate of 33.33333333333333%, average trade percentage of 0.3544089355959463%, and 15 trades. The test showed that the strategy's execution model is not suitable for stocks like RARE that experience large price gaps, as it does not account for fees or slippage and fills stops at the exact stop price even if the price gaps below it. This is contradicted by RARE's actual trading ledger and a 15-minute gap audit. The results of the test cannot be trusted, and no parameters were selected for live use. The test data was sourced from https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all, and additional tests were run using vectorbt calendar tests with exposure audit.

The automated trading fund manager completed an analysis on September 8. The analysis included the following stocks: RARE, IONS, MIRM, and TLX. The manager recorded the following prices and metrics for these stocks: RARE was at 14.88, which is below its 20-day and 50-day Simple Moving Average (a calculation to find the average price of a stock over a certain period) of 24.4385 and 27.3929, with a Relative Strength Index (a measure of how quickly a stock is changing price) of 20.619 and an Average True Range (a measure of how much a stock's price is changing) of 1.949. IONS was at 56.71, below its prices of 59.478 and 60.7466. MIRM was at 99.53, above 99.042 but below 108.5797. TLX was at 11.98, above 11.69075 and 11.2133. The manager noted that the market was in a mixed regime, meaning it was not clearly trending up or down, and no combination of factors fit the data. The manager also calculated the Average Daily Range (the average amount a stock's price changes each day) for TLX and the Average True Range for the stock, which were 0.218205 and 0.388844, respectively. The manager determined that the current market conditions did not indicate a binary gap, which is a large and sudden change in price. The fund had 49.14 dollars available, which would allow for the purchase of at most 4 shares of TLX or 3 shares of RARE at the last closing price, before costs. The manager used 15-minute data from a source called SIP, which provides stock price data, and HTML times from the issuer's website. The manager looked at the prices of IONS and RARE on specific dates: IONS on June 24, RARE on August 19, and RARE on September 2. The manager noted that there were large changes in price for RARE, but did not observe any quotes or fills, which are the prices at which trades are made, and excluded any news that may have caused the changes. The manager also noted that the actual trade of RARE resulted in a loss of 45.86 percent. The manager concluded that relying on whole-share stops, which are orders to buy or sell a stock when it reaches a certain price, is not reliable, especially after hours when the market is not open. The manager did not propose any new stops or targets without a validated edge, which is a proven advantage in the market.

A preregistered note, numbered 1339, was implemented on 1347, before the price outcomes were known. The term T10_T2 refers to the tenth trading session of the second trading period, which is strictly before the issuer's goal. The strategy involves buying at the open and selling at the close, with goals retained on weekends. Ten completed decisions were selected across six issuers, but this is not a complete FDA denominator. Three decisions, MIRM chenodiol 2025, RARE UX111 2025, and NUVL 2026, were resolved before entry and were skipped. The remaining decisions for 2025 include N5, 3TLX, IONS, and SRRK, while the 2026 decisions include IONS olezarsen and RARE DTX401. Advance notices were verified, including the February 23 DTX401 notice. The vectorbt separate event sleeves had equal initial cash, and the portfolio was the sum of the values with idle capital. Overlapping events were not falsely compounded. Fees were 10 basis points plus slippage of 10 basis points on each side, with stress slippage of 30 basis points. An independent closed-form reconciliation passed all 28 event and cost outputs. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all. The data includes paired primary observations from 17167 to 17188, with corrections from 1347 to 17185 to 17187, event rows from 17320 to 17347, and aggregates from 17361 to 17368. The training results for 2025 were: rule T10_T2, year 2025, slippage 0.001, N 5, return percentage 6.5375, drawdown percentage 2.0721, win rate percentage 80, average win percentage 8.9218, average loss percentage 2.9999, mean percentage 6.5375, and confidence interval 0.7997 to 13.2814. The holdout results for 2026 were: rule T10_T2, year 2026, slippage 0.001, N 2, return percentage 3.6779, drawdown percentage 3.0448, win rate percentage 50, average win percentage 10.0230, average loss percentage 2.6672, mean percentage 3.6779, and confidence interval -2.6672 to 10.0230. The stress holdout results for 2026 were: rule T10_T2, year 2026, slippage 0.003, N 2, return percentage 3.2640, drawdown percentage 3.1392, win rate percentage 50, average win percentage 9.5838, average loss percentage 3.0558, mean percentage 3.2640, and confidence interval -3.0558 to 9.5838. Both holdout windows crossed the actual early approval: IONS on June 24 at 14:37:29 ET before the June 26 exit, and RARE on August 19 at 17:22:01 ET before the August 20 exit. The positive 3.6779% return is not a pure pre-news edge, and the N2 bootstrap confidence interval -2.6672 to 10.0230 spans zero. The Gozelli training exit was on March 20, the same US date as the SEC acceptance at 17:34:54 ET, but the earliest FDA/ASX news minute is unresolved, so the exit is retained as ambiguous. No intraday stops or targets were simulated, and fees were assumed not to be venue-invoiced. Daily open and close execution is not guaranteed. This is a diagnostic calendar exposure audit, not a trade-ready strategy. There will be no retuning based on the holdout, and the operational allocation is 0.

A preregistered note, numbered 1339, and implementation, numbered 1347, were made before price outcomes. The term T20_T6 refers to the nth trading session of the SPY, strictly before the issuer's goal, where a buy order is made at the open and a sell order is made at the close, with goals on weekends retained. Ten completed decisions across six issuers were selected, but this is not a complete FDA denominator. The issuers MIRM, chenodiol2025, RAREUX1112025, and NUVL2026 were resolved before entry and were skipped, as they were not post-decision trades. The remaining 2025N5 includes 3TLX, IONS, and SRRK, while 2026N2 includes IONS olezarsen and RARE DTX401. Correct advance notices were verified, including Feb 23 DTX401. The vectorbt separate event sleeves had equal initial cash, with the portfolio being the sum of values and idle capital. Overlapping events were not falsely compounded. Fees were 10 basis points plus slippage of 10 basis points on each side, with stress slippage of 30 basis points. An independent closed-form reconciliation passed all 28 event and cost outputs. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?timeframe=1Day&feed=sip&adjustment=all, which is a data feed. The data includes paired primary observations from 17167 to 17188, with corrections from 1347 to 17185 to 17187, event rows from 17320 to 17347, and aggregates from 17361 to 17368. The training results for 2025 were: return percentage of -8.508057833350623, drawdown percentage of 9.998850991777541, win rate percentage of 20, average win percentage of 1.3646854391706098, average loss percentage of 10.976243651480925, and mean percentage of -8.508057833350618. The holdout results for 2026 were: return percentage of -1.8555954687694776, drawdown percentage of 4.639660087072195, win rate percentage of 0, average win percentage of null, average loss percentage of 1.8555954687694831, and mean percentage of -1.8555954687694831. The stress holdout results for 2026 were: return percentage of -2.2473906718738057, drawdown percentage of 4.929601298264319, win rate percentage of 0, average win percentage of null, average loss percentage of 2.247390671873811, and mean percentage of -2.247390671873811. All seven tested windows finished before known named FDA announcements. This does not establish the absence of other pipeline events or future hazards, and negative costed returns reject the trade rule. No intraday stops or targets were simulated, fees were assumed not to be venue-invoiced, and daily open and close execution was not guaranteed. This is a diagnostic calendar exposure audit, not a trade-ready strategy. There was no retuning based on the holdout, and the operational allocation was 0.

A news scan found regulatory news that affects trading. There are three consequence chains to consider. The first chain, Chain A, happens when a company gets early approval or a Complete Response Letter (CRL), which is a letter from the FDA that says a company's application is not ready for approval. This can cause problems with calendars, which are tools used to keep track of important dates, because they may not be updated to reflect the new information. For example, RARE's UX111 got early approval 138 days ahead of schedule, and GSK's zidesamtinib got approved 58 days early. The second chain, Chain B, happens when there is a problem with filling and finishing a product, which can cause delays and extra spending. This can lead to a higher demand for alternative capacity, but only if the capacity owners have the right qualifications and contracts. The third chain, Chain C, happens when a product in development fails, which can cause the company's stock value to decrease, even if the FDA has a separate goal for the product. For example, RARE's Aspire primary results were announced on September 2. Patients and sponsors can benefit from faster access to new treatments and positive approvals. However, buyers with a lot of cash may also gain power after failures. These are just mechanisms and do not measure how much money competitors make. It is also possible for fast and positive news to reward accidental holding of a stock, but this does not mean that the execution was safe. A new investment is not justified without a clear and independent advantage.

The risk belongs to the issuer's portfolio and manufacturing network. On August 4, RARE's Q2 report, found at https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm, lists UX111 and GTX102 Aspire readouts for September and October. The single named FDA date cannot determine other program news. In Q2, revenue was $214 million, versus $167 million the prior year, a 28.1437% increase. Crysvita made up 72.8972% of revenue, with $156 million. The company had $436 million in cash and investments, and a quarterly operating cash flow burn of $97 million. The static burn, calculated as 436 divided by 97, is 4.4948 quarters or 13.4845 months, but this is an arithmetic calculation, not a forecast, as launch costs, voucher monetization, financing, and planned expense cuts can change it. The net loss of $92 million is not the same as the cash burn of $97 million. Existing commercial cash does not prevent pipeline valuation gaps. On September 2, Ultragenyx announced phase 3 Aspire results for Angelman syndrome, reporting primary and key secondary failure. On September 23, Scholar Rock received a complete response letter for apitegromab. Zircaix's August 28 report cites comparability and third-party manufacturing issues. These examples illustrate common network risk, not clinical approval odds or independent trials. A valid inference is to review the whole pipeline and shared suppliers before exposure. The strongest counterexample is that multiproduct commercial revenue can cushion losses, but RARE's actual gap shows cushioning is not guaranteed. Current market valuation and incremental product NPV are not estimated, and no price target or probability derives from sales growth. A news scan found the headline about Ultragenyx's announcement, which is a news release.

At 02UTC, the decision was made to preserve $49.14 and retain the new Darden paper study. The start state was $49.14 in cash and an account balance of $850.99, with no positions or queued orders. The goal is to achieve repeatable costed run-ups that are exited before dated events. A binding constraint is an independently credible actual-window payoff plus executable risk. The premises coverage audit screened 12,647 US symbols and 232 JPX September event rows, with explicit syntax gaps. The DRI study showed a 5.6622% increase, with a mean confidence interval of -0.8285% to 2.9660%. A positive result merits watch, but does not force a negative conclusion. The empirical quarter Kelly is 0.073922. The current window starts on September 17. There are regulatory uncertainties with MRK, and PPIH and WLTH have no remaining validated multi-session window. The fund cap is $49.14, and the venue position cap is $212.7475. A strongest counterargument is that a positive net DRI holdout may represent a real edge. No propose, exit, adjust, or fund actions were taken. The earlier negative AVO rule remains unchanged. Sources include investor news from Darden Restaurants. A new monitor was rejected, and a standalone collector was also rejected. A tested coverage-preserving replacement is now active. Research ended around 02:19UTC, with 12 minutes of discovery cut enforced and the final recording reserve used. Named gaps remain, and were not guessed.

An audit of the real listing screen and calendar transport found the following results. On September 8 at 21:31, the Nasdaq Trader directories at https://www.nasdaqtrader.com/dynamic/SymDir/nasdaqlisted.txt and https://www.nasdaqtrader.com/dynamic/SymDir/otherlisted.txt yielded 13,156 non-test rows, with 13,155 unique rows. After excluding 384 unsupported preferred symbols and repairing 32 batches, 12,771 requested and 12,647 returned rows were covered, with 124 missing. The source of this data is https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex. A screen with a price of $1 to $49.14, IEX dollars greater than or equal to $100,000, and a positive prior close gave 959 results, including ETFs, but not all 959 were eligible catalysts. There were 16 calendar timeouts on Nasdaq and 14 Yahoo date URLs returning identical rows on September 9, meaning the broad future earnings intersection remains incomplete. Direct issuer recovery confirmed DRISep24, PPIHSep9BMO, WLTHSep9AMC, and NUVLJuly22 FDA approval supersedes the stale September 18 goal. The JPX website at https://www.jpx.co.jp/listing/event-schedules/financial-announcement/index.html contains July and August quarter spreadsheets with 656 dated rows and 232 September 9-30 events. The issuer confirmed ASKULSep15, KGFSep22 is provisional, and existing NXT/ITX watches are in place. This is not an exhaustive world exchange census, and foreign venue, FX, lot, and costed edge are unverified. There were 39 completed daily bars each for BTC, ETH, and SOL, with partial exclusion on September 9. The 5-day returns were -3.471%, -0.944%, and -0.585% respectively, with no earnings or FDA linkage. The ETH Sepolia October 6 later developer decision at https://ethereum-magicians.org/t/all-core-devs-consensus-acdc-186-september-3-2026/29496 supersedes the August 6 overview on September 28, with the mainnet unconfirmed. The scope creep into an untested upgrade book was rejected. The top selected primary sources and financial rejections recorded 1372-83. All scans are descriptive, not backtested or qualified entry signals. The discovery cut was at 12 minutes as planned, and the calendar coverage gap was retained rather than borrowing from the finish reserve. A news scan found the headline, but it is not included here as it is not relevant to the audit results.

A fund manager is analyzing Darden Restaurants, ticker DRI, and the SPY index. The manager's model has a 50% chance of a positive outcome, with a 3.216773% win and a 1.314447% loss, and a mean return of 0.951163%. A bootstrap analysis shows that 82.19% of sample means are positive, but this is not the probability of a successful trade. The manager also ran a regression analysis on DRI and SPY returns, finding a correlation of -0.730141 and a beta of -1.272867. The mean return of DRI minus SPY is 1.571702%, but this result is not stable. The manager calculated the Kelly fraction, a measure of optimal bet size, to be 0.073922, but due to uncertainty, the operational fraction is set to 0. The manager's ledger shows three losses, with a mean loss of -16.3806%, and no winners to calibrate the average win. A loss of 45.86% shows that stops are not hard loss bounds. The analysis is based on 16251-74 events from https://runway.adityaperswal.workers.dev/data/stock-bars and https://runway.adityaperswal.workers.dev/query_trades. The results have limited validity due to the selected issuer and incomplete training notice history. The manager will change the allocation if independent future events support a positive costed actual-window expectancy with adequate uncertainty and executable risk plan.

A news scan found a report about Darden event bootstrap. The report used data from DRI SEC releases and a website to look at cash returns from 16251 to 1656. It used a computer program called NumPy with a seed of 20260909 to create 50000 different paths of ten events, starting at 49.14 dollars and reinvesting at each event. The results showed that the median, or middle, outcome was 53.8006 dollars, with 11.128 percent of the paths resulting in a loss. The worst loss in the top 5 percent of paths was 7.4522 percent. Another calculation showed that the average outcome could be between -0.8285 percent and 2.9660 percent, which includes zero. This is based on the idea that the six observed outcomes are representative and independent. However, this simulation does not take into account things like large gaps in data, changes in the market, taxes, or actual execution failures. No real money was invested. One example that goes against this simulation is an unobserved event where there was a realized loss of 45.86 percent. The simulation should not be used to predict actual losses or probabilities. It is meant to inform research, not authorize investment. A quarter Kelly estimate of 0.073922 was overridden by other evidence to 0.

The primary dates for consideration are: Darden Restaurants' fiscal 2027 first-quarter results release on September 24, 2026, before the market opens; Perma-Pipe's second-quarter 2026 results report on September 9, 2026, before the market opens; Wealthfront's report on September 9, 2026, after the market closes; and Merck's goal on September 21, 2026. Darden Restaurants has a fixed entry start date of September 17, so buying early changes the tested window. Its close below the 20-day Simple Moving Average and above the 50-day Simple Moving Average, a type of stock price trend indicator, is not a trained combined filter. Perma-Pipe and Wealthfront pass the affordability and positive prior-close screening, a check to see if the stock price is reasonable and was positive the day before, but they lack a remaining tested multi-session window; their price and volume quotes from the Investors Exchange are partial and their closing quotes are stale, meaning not up to date. Darden Restaurants' holdout uncertainty, a measure of uncertainty in the data not used for training, crosses zero, and its training advance notices are incomplete; Merck has no actual-window payoff sample, a sample of data showing the return on investment during a specific time period. Whole-share and fund/venue/risk limits, restrictions on the amount of money that can be invested, apply only after edge qualification, a measure of the advantage of a particular investment. In conclusion, there are zero combined qualified candidates; a date or positive market trend alone cannot substitute for all the requirements. The strongest counterexample is that affordable one-session rallies, a quick increase in stock price, can occur; these require a separate preregistered net rule, a set of rules for investing, not inherited five-session odds, the probability of a stock price moving in a certain way over five sessions.

A news scan found the analysis of Darden's stock. The analysis used a source from https://runway.adityaperswal.workers.dev/data/stock-bars, which provided data on DRI stock bars. As of the close on September 8, the stock price was 212.92, which is below the 20-day Simple Moving Average of 219.5185, but above the 50-day Simple Moving Average of 209.3456. The five-session return was -0.6254%. The Average True Range over 14 days was 5.4490 and the Average Daily Range over 20 days was 5.4510. The recent low was 210.86 and the recent high was 229.7625, with a Realized Volatility over 20 days of 30.8874% annualized. The premises for the analysis were that the daily trend is mixed, the fixed event entry is September 17 rather than today, and one share exceeds the 49.14 fund cap. A one-to-two-ADR upside reference is about 5.45-10.90 USD, but this is not a proposed target and cannot validate a stop or expected return by itself. A counterexample recovery above the short average could precede earnings strength, but adding this filter now would change the registered rule. As a result, there will be no entry, exit, or stop adjustment, and the position will be booked flat. Additionally, it was noted that IEX screen data from other sources are a different feed from these SIP adjusted bars, and daily history cannot establish 15-minute execution.

A computer program ran a test on the stocks DRI and MRK using a momentum strategy, which means it looked at how the prices of the stocks were changing to decide when to buy or sell. The test used 1001 days of stock prices and made 133 trades. The test was done using a program called node and a file called backtest.js, and it got its stock price information from a website. The test did not take into account any fees or costs that might be associated with actually buying or selling the stocks, and it did not set aside any time periods to see how the strategy would work in the future. The test found that the strategy worked for MRK, but this does not mean that it would work in real life, especially around certain events like when a company reports its earnings or when a drug is approved by the government. The results of the test were stored in a file called cli_dri_mrk.json. A news scan found the headline that the test results were positive for MRK, but this cannot be used to predict how the stock will do in the future, so the strategy should not be adopted.

A test was run using a computer program to analyze the stocks DRI and MRK using a momentum strategy, which is a way of making investment decisions based on the stock's price trends. The test looked at 1001 days of stock prices and made 127 trades. The test used data from the website https://runway.adityaperswal.workers.dev/data/stock-bars. This test did not take into account the timing of certain events or any fees that might be charged, and it assumed that the stock prices would stop or reach a target every day. The test results do not prove that the strategy would work in real-life situations, such as during earnings reports or before certain regulatory decisions. A separate test was done on DRI that included costs and a holdout period, which is a way of testing a strategy without using all of the available data. The results of the test on MRK cannot be applied to a different time period, such as September 2021. The test results suggest that the generic rules used in the test should not be adopted. The results of the test are stored in a file called cli_dri_mrk.json.

A note was registered before inspecting the price, with a plan to enter at the open five trading sessions before the event and exit at the close one session before the event, avoiding any event exposure. The primary release dates were obtained from 18 SEC exhibits, with observations from 16251 to 16274. Six advance notices were verified 28 to 29 days before the release, with URLs listed in note 1299. The training data used was from 2022 to 2024, with 12 observations, and the holdout data was from 2025 to June 2026, with 6 observations. The vectorbt system was used with 10 basis point fees and 10 basis point slippage per side, and the daily high, low, open, and close prices were adjusted. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=DRI,SPY&timeframe=1Day&start=2021-12-01T00:00:00Z&end=2026-09-09T00:00:00Z&feed=sip&adjustment=all. The training net return was 1.4581%, with a maximum drawdown of 6.6115%. The holdout net return was 5.6622%, with a maximum drawdown of 4.9869%, and a cash-basis mean of 0.951163%. The average win was 3.216773%, and the average loss was 1.314447%. Even with increased slippage and fees, the net return was still 3.7773%. Six training sensitivities were recorded, with returns ranging from -4.3463% to 9.3334%. A bootstrap analysis with 50,000 iterations had a mean 95% confidence interval of -0.8285% to 2.9660%, which includes zero. The historical training notice vintages were incomplete, and the adjusted bars do not establish actual auction or 15-minute stop fills. The positive evidence merits a prospective watch, but not adoption. The strongest counterargument is the real positive costed holdout, which changes the research priority but not the size until uncertainty and execution gates pass. The current primary notice is https://investor.darden.com/news/news-details/2026/Darden-Restaurants-to-Release-Fiscal-2027-First-Quarter-Results-on-September-24-2026/default.aspx, with a planned entry on September 17 and exit on September 23, not today. The local reproducible code is dri_test.py/dri_test.json. The trade payoff statistics use the net cash invested, including entry fees.

The fund manager has analyzed several companies, including DRI, MRK, KGF, and ASKUL. For DRI, there are three key points: first, traffic and mix affect headline growth, with an extra week having an impact; second, food and labor costs, as well as $875 million in planned capital expenditures, compete for cash; and third, cash after investment versus dividend and buybacks determines financing needs. The beneficiaries of this situation are customers, workers, suppliers, and repurchasing shareholders. A countercase is that positive comparisons and cash growth can lead to sustainable expansion. For MRK, the three key points are: first, a broader HYPERION label may expand eligible patient and treatment timing; second, physicians, payers, and adverse event monitoring determine actual uptake, while BMS receives a 22% net sales royalty; and third, retained cash, net of commercial and research costs, determines MRK's value. A countercase is that the label adds little after prior ZENITH approval or payers limit use. For KGF, the key points are: first, housing and DIY demand changes volumes; second, promotions and finance costs offset sales; and third, free cash flow and working capital decide buyback capacity. A countercase is that an improved mix sustains earnings. For ASKUL, the key points are: first, resolved login issues may restore orders; second, repeat purchasing and fulfillment cost decide actual recovery; and third, retained cash and trust determine value. A countercase is that resolved bugs are immaterial to the quarter. All of these hypotheses are conditional and not measured against peer profits. No separate fund is justified without costed payoff evidence.

The Darden Restaurants company has confirmed that it will release its fiscal 2027 first quarter results on September 24, 2026, as stated in a notice on August 27. A Securities and Exchange Commission filing on June 25 reports a 53-week fiscal year with 13.7% growth in the fourth quarter, which includes a 7.6% increase due to an extra week. The company's operating cash flow, minus property and capital expenditures, was $1,096.2 million, which is a 5.41% increase. The company also reported $1,364.7 million in shareholder returns, exceeding $268.5 million, and net short-term debt of $194 million. The estimated earnings per share for fiscal year 2027 is $11.10 to $11.35, with capital expenditures of $875 million. A news scan found the headline of a Merck June 30 filing, which confirms a September 21 label review for HYPERION. The company's revenue for the second quarter was $5,880 million, with a 3.54% increase, and the company received $166.07 million from BMS royalty, implying $129.36 million, but not actual cash received. The company also has an existing ZENITH approval and a competing pipeline. The Kingfisher company has explicitly stated that its prior guidance for profit before tax and free cash flow is provisional, and the ASKUL company has announced a September 15 date, but has not quantified customer churn. These facts inform watchlists, but do not provide a trading edge. The primary issuer is incentivized to frame information in a certain way, and there are gaps in the cost of foreign venues. The starting cash is $49.14, and the binding constraint is the costed actual window uncertainty. These candidates improve diversity, but do not authorize allocation.

At 00UTC, the research decision was made to preserve $49.14. No holdings require changes to exit. The account started with $49.14 in cash and $850.99 in equity, with no open, pending, or closing positions. The goal is to achieve repeatable gains before events happen, based on a validated expectancy for the entry and exit window. Two premises support this decision: first, an audit confirmed no live thesis to reset and no monitor due before the next 02UTC run; second, analyses recovered primary tables for BRZE and GME, and rejected an unverified FedEx September calendar date. The primary sources for these analyses include SEC filings and company news releases. A third premise is that saved AVO expectancy and TLX event sample imply no positive edge. The conclusion is to not propose, exit, adjust, or fund any positions. The strongest counterargument is the opportunity cost of cash, but it does not provide the necessary win/loss figures. No targets or stops were fabricated for nonexistent positions. The system will retain 20 armed monitors and 5 collectors, with 48 scheduled for 00:15, 67 for 00:30, and 52 for 01:30 before the next 02UTC run. Existing static monitors remain unarmed. The journal phase began at 00:04:46, within the planned 43-minute budget.

An audit of a trading fund's payoff has kept the position size at zero. The audit is based on several premises. First, the fund's trade history shows three losses: MIRM lost 0.439321%, IONS lost 2.842420%, and RARE lost 45.860062%, with an average loss of 16.380601%. Two of these losses were due to the operator liquidating the positions, so this is not a representative sample of the strategy's performance. There were no winning trades, so the average winning payoff is unknown. Second, the loss on RARE was 6.440348 times the distance from the entry point to the listed stop, showing that the stop did not limit the loss. Third, a backtest of the AVO stock using the vectorbt system with 10 basis point fees and 10 basis point slippage per side showed a negative net return of 7.331815% and a drawdown of 9.371961%. All 16 variants of the backtest lost money. A Python recalculation confirmed that the quarter-Kelly strategy should have a position size of zero. Fourth, an audit of the TLX event showed no valid training events and only one positive holdout, and the momentum503 strategy failed to predict the outcome. The sources of this information include the Catalyst trade history, backtest analyses, and stock price data. The valid inference from this audit is that there is no evidence of a positive edge to support a position size greater than zero. However, it is possible that future price increases could result in wins, and these small samples do not prove that the market is always efficient. No new backtests or data collection are claimed, and existing failed methods have not been revised. The calculations from Observation16039 have been preserved.

The following are conditional watchlist theses, not current positions. For Braze Inc, or BRZE, a source from https://www.sec.gov/Archives/edgar/data/1676238/000167623826000039/a20260731-brazeincxq227ear.htm notes three points: 1, services and Artificial Intelligence adoption increase implementation work; 2, cloud and data implementation providers may collect spend while BRZE's gross mix dilutes; 3, renewals and net dilution decide shareholder cash. On the other hand, successful automation improves retention and scales high margin recurring revenue. For GameStop Corp, or GME, a source from https://www.sec.gov/Archives/edgar/data/1326380/000132638026000050/a991-fy26q2earningsrelease.htm notes: 1, collectibles mix supports retail gross profit; 2, popularity cycle, suppliers, and tax or receivables affect conversion; 3, eBay investment concentration can amplify capital volatility independent of store profits. Conversely, first half cash growth and debt exchange improve resilience. For Telix Pharmaceuticals, or TLX, a source from https://telixpharmaceuticals.gcs-web.com/news-releases/news-release-details/telix-2026-half-year-results-strong-commercial-execution-and notes: 1, regulatory outcome affects launch or Chemistry, Manufacturing, and Controls work; 2, distribution capacity requires investment before utilization; 3, pipeline cash returns versus financing or dilution decide retained value. On the other hand, a commercial franchise absorbs investment and new approvals fill capacity. For Mission Produce, or AVO, prior observation 15974 and a source from https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial note: 1, acquired volume or unit price is down; 2, grower margins and working capital are pressured; 3, integration or seasonality decides debt capacity; a countercase forecast realizes synergies. For Casey's General Stores, or CASY, prior observation 15975 and a source from https://investor.caseys.com/news-releases/news-release-details/caseys-announces-first-quarter-results-3 note: 1, fuel spread normalizes; 2, gross profit funding for stores falls; 3, capital expenditure return or inside growth must offset; a countercase inside growth and persistent spreads sustain profit. These sources are from the issuer, not independent causal identification. Rates and totals are observed from 15974 to 15975 and 16012 to 16016; no peer profit or stock probabilities are estimated, and no new fund is justified.

A news scan found the headline about Telix economics and FedEx fiscal change. Telix Pharmaceuticals announced its 2026 half-year results on August 20, confirming strong commercial execution and a September 11 PDUFA, or Prescription Drug User Fee Act, decision for Pixclara. The company excluded Pixclara from its full-year revenue guide. The first half EBITDA was $52 million, which includes a $40 million upfront payment. Subtracting the upfront payment gives a $12 million arithmetic sensitivity, not a normalized estimate. The company reported a $23 million loss in TMS, or Treasury Management System, versus $13 million, and $124 million in research and development expenses versus $82 million. The company had $252 million in cash and $23 million in operating cash flow, which is positive. A bear case scenario suggests that upfront and commercial growth may mask investment spending, and another pipeline CMC, or Chemistry, Manufacturing, and Controls, setback can overwhelm the run-up in Pixclara. A counter case scenario suggests that an established imaging franchise and funding can absorb research and approval may unlock future economics. There is no approved label or sales forecast inferred. FedEx announced a change in its fiscal year from May 31 to December 31, starting June 1, and discontinued its Freight segment. A third-party estimate on September 17 based on the old calendar failed to meet the primary date gate. The company's investor relations website did not provide any new exact date. Oxford Industries and Lands' End announced their second-quarter fiscal 2026 results on September 3. A search for UK's John Lewis 2025 half-year results was stale. The validity of dates and cash source is separate from expectancy. A soundness-selected search is not exhaustive global coverage. An existing Telix test with 500 training data and 0 holdout data cannot estimate edge, and zero allocation was made. No new regulatory decision was found in the scoped search, which is not exhaustive, and the absence of a decision was not verified. The monitor 22 and collector 52 were retained.

A news scan found the headline about GameStop's bear case. The company's earnings release for the second quarter of 2026 is available at https://www.sec.gov/Archives/edgar/data/1326380/000132638026000050/a991-fy26q2earningsrelease.htm. The operating profit was $160.2 million, which is within the preliminary range of $150-170 million. The EBITDA, or earnings before interest, taxes, depreciation, and amortization, a measure of a company's overall financial performance, floor was raised to more than $650 million from more than $600 million. The free cash flow, or the amount of cash a company has after paying expenses, for the second quarter was $60.7 million, compared to $113.3 million in the same period last year. The pretax profit was $420.2 million, which is $260 million more than the operating profit, and includes $43.4 million from eBay shares worth $4.9469 billion. The company paid $4.3863 billion in cash for equity in the quarter. The strongest bear case, or argument for why the company's stock will decline, is that the popularity of collectibles may fade, and the company's investment concentration and use of cash for working capital and taxes may stress its cash conversion. However, the company's retail operating profit more than doubled, and its inventory increased from $439 million to $484.9 million. The company's annual cash flow is improving, and it has completed a debt exchange. One quarter of cash decline does not necessarily mean a long-term collapse. The validity of the company's financial statements depends on reading its retail and investment segments separately, and the soundness of the unaudited issuer statements, not third-party confirmation. The contradiction between the quarter and half-year cash flow is resolved by considering the period and timing, and the debt of $4.1678 billion on August 1 differs from the $2.8 billion post-exchange on September 3. There were no Bitcoin sales, with a quantity of 75mm or $294.1 million in assets or receivables aggregate. The company's optimistic EBITDA framing benefits the issuer, collectible suppliers, and concentrated equity holders, but there is no cross-company payoff inferred. There is no independent post-event edge, and the price or valuation cannot be measured, so it cannot be called cheap. The monitor will retain a zero entry for the next day's context.

A news scan found the SEC exhibit for Braze Inc, which was retrieved from https://www.sec.gov/Archives/edgar/data/1676238/000167623826000039/a20260731-brazeincxq227ear.htm. This exhibit shows that on September 8, the company reported its Q2 revenue as $227.230 million, with a subscription revenue increase of 20.8964% compared to the total revenue increase of 26.2%. The services revenue accounted for approximately 24% of the incremental revenue. The gross margin decreased by 90 basis points, which means it decreased by 0.9%. The free cash flow was $21.744 million, but the stock-based compensation was $35.661 million, and the GAAP operating profit was -$18.123 million, compared to a non-GAAP operating profit of $22 million. In the first half of the year, the deferred revenue cash contribution increased by $27.972 million, which exceeds the operating cash flow improvement of $21.242 million. The strongest bear case is that the service implementation mix and prepayments can boost headline growth and cash flow before durable high-margin recurring returns, and dilution consumes part of shareholder benefit. However, a counterexample shows that subscription growth of approximately 21%, retention of 110% versus 108%, falling stock-based compensation, and stronger free cash flow support real operating improvement. It is not accurate to call the reported cash flow fake or the free cash flow less stock-based compensation actual cash burn. The validity metrics cannot identify priced-in surprise or return probability, and the soundness is limited by one unaudited issuer origin, organic bridge, and call replay missing. The customers may gain automation, employees receive equity, and the issuer favors adjusted profit framing. The start cash is the binding constraint, and the independent actual window payoffs are the key. This research is only for informational purposes, as the pre-earnings window is now closed. The evidence for moving allocation is based on an independently frozen post-event rule with positive costed out-of-sample expectancy and uncertainty, and 15-minute fills, but until then, it is not a numerical probability guessed from business growth.